Piracetam and dyslexia: effects on reading tests
Related Experiment Videos
Insights
Piracetam significantly improved reading skills and comprehension in dyslexic children over 36 weeks. This study found piracetam (a nootropic drug) to be well-tolerated and effective for dyslexia treatment.
Area of Science:
- Neuroscience
- Developmental Psychology
- Pharmacology
Background:
- Previous studies indicated piracetam may enhance cognitive functions in individuals with dyslexia.
- Dyslexia is a neurodevelopmental disorder affecting reading acquisition.
Purpose of the Study:
- To evaluate the efficacy and safety of piracetam in improving reading skills in dyslexic children.
- To assess the long-term effects of piracetam treatment on reading ability and comprehension.
Main Methods:
- A 36-week, multicenter, double-blind, placebo-controlled trial involving 225 dyslexic children (ages 7-12).
- Exclusion criteria ensured a homogenous sample, excluding children with other neurological, psychiatric, or sensory impairments.
- Standardized reading tests (Gray Oral Reading Test, Gilmore Oral Reading Test) were used for assessment.
Main Results:
- Piracetam-treated children demonstrated statistically significant improvements in reading ability and comprehension compared to the placebo group.
- Treatment effects were observable by 12 weeks and maintained throughout the 36-week study period.
- Piracetam was well-tolerated, with no significant adverse clinical or laboratory effects reported.
Conclusions:
- Piracetam is a safe and effective therapeutic agent for enhancing reading skills and comprehension in dyslexic children.
- The positive effects of piracetam on reading performance are sustained over a 36-week treatment period.
Abstract:
Previous research has suggested that dyslexics treated with piracetam have shown improvements in reading skills, verbal memory and verbal conceptualizing ability, feature analysis, and processing of letter-like stimuli. Two hundred twenty-five dyslexic children between the ages of 7 years 6 months and 12 years 11 months whose reading skills were significantly below their intellectual capacity were enrolled in a multicenter, 36-week, double-blind, placebo-controlled study. Children of below average intelligence, with abnormal findings on audiologic, ophthalmologic, neurologic, psychiatric, and physical examinations, who were emotionally disturbed or educationally deprived and who had recently been treated with psychoactive medication were excluded from the trial. Piracetam was well tolerated, with no serious adverse clinical or laboratory effects reported. Piracetam-treated children showed significant improvements in reading ability (Gray Oral Reading Test) and reading comprehension (Gilmore Oral Reading Test). Treatment effects were evident after 12 weeks and were sustained for the total period (36 weeks).